Tetra Technologies, Mesa Royalty Trust, Another 7 Companies Have A High Estimated Dividend Yield

(VIANEWS) – Tetra Technologies (TTI), Mesa Royalty Trust (MTR), Sotherly Hotels (SOHON) have the highest dividend yield stocks on this list.

Almost 2K companies listed in the Nasdaq and NYSE pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. Tetra Technologies (TTI) – Dividend Yield: 21.57%

Tetra Technologies’s last close was $5.58, 17.58% below its 52-week high of $6.77. Intraday change was 0.54%.

TETRA Technologies, Inc., together with its subsidiaries, operates as an energy services and solutions company. It operates through two segments, Completion Fluids & Products Division and Water & Flowback Services. The Completion Fluids & Products segment manufactures and markets clear brine fluids, additives, and associated products and services to the oil and gas industry for use in well drilling, completion, and workover operations in the United States, as well as in Latin America, Europe, Asia, the Middle East, and Africa. This segment also markets liquid and dry calcium chloride products; and TETRA PureFlow ultra-pure zinc bromide to battery technology companies. The Water & Flowback Services segment provides water management services for onshore oil and gas operators. This segment also offers frac flowback, production well testing, and other associated services in oil and gas producing regions in the United States and Mexico, as well as in various basins in Latin America, Africa, Europe, and the Middle East. The company was incorporated in 1981 and is headquartered in The Woodlands, Texas.

Earnings Per Share

As for profitability, Tetra Technologies has a trailing twelve months EPS of $0.18.

PE Ratio

Tetra Technologies has a trailing twelve months price to earnings ratio of 31. Meaning, the purchaser of the share is investing $31 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.43%.

Volume

Today’s last reported volume for Tetra Technologies is 910957 which is 51.42% below its average volume of 1875480.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend rate is 2.01 and the estimated forward annual dividend yield is 21.57%.

More news about Tetra Technologies.

2. Mesa Royalty Trust (MTR) – Dividend Yield: 13.21%

Mesa Royalty Trust’s last close was $13.08, 55.66% below its 52-week high of $29.50. Intraday change was -1.36%.

Mesa Royalty Trust owns net overriding royalty interests in various oil and gas producing properties in the United States. The company has interests in properties located in the Hugoton field of Kansas; and the San Juan Basin of Northwestern New Mexico and Southwestern Colorado. Mesa Royalty Trust was founded in 1979 and is based in Houston, Texas.

Earnings Per Share

As for profitability, Mesa Royalty Trust has a trailing twelve months EPS of $2.4.

PE Ratio

Mesa Royalty Trust has a trailing twelve months price to earnings ratio of 5.45. Meaning, the purchaser of the share is investing $5.45 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 163.32%.

Moving Average

Mesa Royalty Trust’s worth is way under its 50-day moving average of $16.18 and way under its 200-day moving average of $19.11.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Sep 27, 2023, the estimated forward annual dividend rate is 1.94 and the estimated forward annual dividend yield is 13.21%.

Yearly Top and Bottom Value

Mesa Royalty Trust’s stock is valued at $13.08 at 04:15 EST, way below its 52-week high of $29.50 and above its 52-week low of $12.80.

More news about Mesa Royalty Trust.

3. Sotherly Hotels (SOHON) – Dividend Yield: 9.21%

Sotherly Hotels’s last close was $22.39, 15.19% below its 52-week high of $26.40. Intraday change was -2.35%.

Sotherly Hotels Inc. is a self-managed and self-administered lodging REIT focused on the acquisition, renovation, upbranding and repositioning of upscale to upper-upscale full-service hotels in the Southern United States. Currently, the Company's portfolio consists of investments in twelve hotel properties, comprising 3,156 rooms, as well as interests in two condominium hotels and their associated rental programs. The Company owns hotels that operate under the Hilton Worldwide, Hyatt Hotels Corporation, and Marriott International, Inc. brands, as well as independent hotels. Sotherly Hotels Inc. was organized in 2004 and is headquartered in Williamsburg, Virginia.

Earnings Per Share

As for profitability, Sotherly Hotels has a trailing twelve months EPS of $-1.66.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.02%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Aug 29, 2023, the estimated forward annual dividend rate is 2.06 and the estimated forward annual dividend yield is 9.21%.

Volume

Today’s last reported volume for Sotherly Hotels is 1050 which is 25.89% below its average volume of 1417.

Moving Average

Sotherly Hotels’s value is below its 50-day moving average of $23.44 and under its 200-day moving average of $24.16.

Revenue Growth

Year-on-year quarterly revenue growth grew by 3.9%, now sitting on 173M for the twelve trailing months.

More news about Sotherly Hotels.

4. First Trust MLP and Energy Income Fund (FEI) – Dividend Yield: 7.78%

First Trust MLP and Energy Income Fund’s last close was $8.31, 2.46% under its 52-week high of $8.52. Intraday change was -0.48%.

First Trust MLP and Energy Income Fund is a closed-ended balanced mutual fund launched and managed by First Trust Advisors L.P. The fund is co-managed by Energy Income Partners LLC. It invests in the public equity and fixed income markets of the United States. The fund seeks to invest in securities of companies operating in the energy and energy utilities sectors. It primarily invests in equity and debt securities of MLPs and MLP-related entities, as well as in dividend paying growth stocks of companies. First Trust MLP and Energy Income Fund was formed on August 17, 2012 and is domiciled in the United States.

Earnings Per Share

As for profitability, First Trust MLP and Energy Income Fund has a trailing twelve months EPS of $0.58.

PE Ratio

First Trust MLP and Energy Income Fund has a trailing twelve months price to earnings ratio of 14.33. Meaning, the purchaser of the share is investing $14.33 for every dollar of annual earnings.

Yearly Top and Bottom Value

First Trust MLP and Energy Income Fund’s stock is valued at $8.31 at 04:15 EST, under its 52-week high of $8.52 and way higher than its 52-week low of $7.02.

Volume

Today’s last reported volume for First Trust MLP and Energy Income Fund is 302591 which is 220.94% above its average volume of 94281.

Moving Average

First Trust MLP and Energy Income Fund’s value is above its 50-day moving average of $7.97 and higher than its 200-day moving average of $7.84.

More news about First Trust MLP and Energy Income Fund.

5. Photronics (PLAB) – Dividend Yield: 4.76%

Photronics’s last close was $19.82, 26.54% under its 52-week high of $26.98. Intraday change was 3.61%.

Photronics, Inc., together with its subsidiaries, engages in the manufacture and sale of photomask products and services in the United States, Taiwan, Korea, Europe, China, and internationally. The company offers photomasks that are used in the manufacture of integrated circuits and flat panel displays (FPDs); and to transfer circuit patterns onto semiconductor wafers, FDP substrates, and other types of electrical and optical components. It sells its products to semiconductor and FPD manufacturers, designers, and foundries, as well as to other high-performance electronics manufacturers through its sales personnel and customer service representatives. The company was formerly known as Photronic Labs, Inc. and changed its name to Photronics, Inc. in 1990. Photronics, Inc. was incorporated in 1969 and is based in Brookfield, Connecticut.

Earnings Per Share

As for profitability, Photronics has a trailing twelve months EPS of $1.91.

PE Ratio

Photronics has a trailing twelve months price to earnings ratio of 10.38. Meaning, the purchaser of the share is investing $10.38 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.45%.

Yearly Top and Bottom Value

Photronics’s stock is valued at $19.82 at 04:15 EST, way below its 52-week high of $26.98 and way higher than its 52-week low of $13.86.

Moving Average

Photronics’s value is under its 50-day moving average of $20.31 and under its 200-day moving average of $19.96.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1.9%, now sitting on 874.87M for the twelve trailing months.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 4.76%.

More news about Photronics.

6. Perrigo Company plc Ordinary Shares (PRGO) – Dividend Yield: 4%

Perrigo Company plc Ordinary Shares’s last close was $26.98, 33.63% under its 52-week high of $40.65. Intraday change was -5.53%.

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the brand names of Prevacid, 24HR, Good Sense, Zephrex D, ScarAway, Plackers, and Rembrandt. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands and consumer focused products through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 30 countries, primarily in Europe. The Prescription Pharmaceuticals segment develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Earnings Per Share

As for profitability, Perrigo Company plc Ordinary Shares has a trailing twelve months EPS of $-0.42.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.17%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 8.9% and 22.7%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth grew by 6.4%, now sitting on 4.63B for the twelve trailing months.

Sales Growth

Perrigo Company plc Ordinary Shares’s sales growth is 5.3% for the current quarter and 8.9% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Perrigo Company plc Ordinary Shares’s EBITDA is 51.92.

More news about Perrigo Company plc Ordinary Shares.

7. Baxter International (BAX) – Dividend Yield: 3.42%

Baxter International’s last close was $32.83, 42.32% under its 52-week high of $56.92. Intraday change was -0.61%.

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules; and a collaborative research agreement with Miromatrix Medical Inc. to develop treatments for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is based in Deerfield, Illinois.

Earnings Per Share

As for profitability, Baxter International has a trailing twelve months EPS of $0.46.

PE Ratio

Baxter International has a trailing twelve months price to earnings ratio of 70.93. Meaning, the purchaser of the share is investing $70.93 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.42%.

Sales Growth

Baxter International’s sales growth is negative 2.1% for the ongoing quarter and negative 1.7% for the next.

More news about Baxter International.

8. NextEra Energy (NEE) – Dividend Yield: 3.33%

NextEra Energy’s last close was $54.72, 38.25% under its 52-week high of $88.61. Intraday change was 0.44%.

NextEra Energy, Inc., through its subsidiaries, generates, transmits, distributes, and sells electric power to retail and wholesale customers in North America. The company generates electricity through wind, solar, nuclear, coal, and natural gas facilities. It also develops, constructs, and operates long-term contracted assets that consists of clean energy solutions, such as renewable generation facilities, battery storage projects, and electric transmission facilities; sells energy commodities; and owns, develops, constructs, manages and operates electric generation facilities in wholesale energy markets. As of December 31, 2022, the company had approximately 32,100 megawatts of net generating capacity; approximately 88,000 circuit miles of transmission and distribution lines; and 871 substations. It serves approximately 12 million people through approximately 5.8 million customer accounts in the east and lower west coasts of Florida. The company was formerly known as FPL Group, Inc. and changed its name to NextEra Energy, Inc. in 2010. NextEra Energy, Inc. was founded in 1925 and is headquartered in Juno Beach, Florida.

Earnings Per Share

As for profitability, NextEra Energy has a trailing twelve months EPS of $3.79.

PE Ratio

NextEra Energy has a trailing twelve months price to earnings ratio of 14.5. Meaning, the purchaser of the share is investing $14.5 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.84%.

Volatility

NextEra Energy’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.23%, a positive 0.51%, and a positive 1.63%.

NextEra Energy’s highest amplitude of average volatility was 1.23% (last week), 1.81% (last month), and 1.63% (last quarter).

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Nov 21, 2023, the estimated forward annual dividend rate is 1.87 and the estimated forward annual dividend yield is 3.33%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NextEra Energy’s stock is considered to be overbought (>=80).

Earnings Before Interest, Taxes, Depreciation, and Amortization

NextEra Energy’s EBITDA is 6.77.

More news about NextEra Energy.

9. Cumberland Pharmaceuticals (CPIX) – Dividend Yield: 2.07%

Cumberland Pharmaceuticals’s last close was $1.78, 38.83% under its 52-week high of $2.91. Intraday change was -5.82%.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Earnings Per Share

As for profitability, Cumberland Pharmaceuticals has a trailing twelve months EPS of $-0.12.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.86%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 5.7%, now sitting on 40.65M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Cumberland Pharmaceuticals’s EBITDA is 11.25.

Yearly Top and Bottom Value

Cumberland Pharmaceuticals’s stock is valued at $1.78 at 04:15 EST, way under its 52-week high of $2.91 and way higher than its 52-week low of $1.43.

Moving Average

Cumberland Pharmaceuticals’s value is under its 50-day moving average of $1.91 and under its 200-day moving average of $1.91.

More news about Cumberland Pharmaceuticals.